SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for SCYNEXIS INC (SCYX) (CIK 0001178253) (SCYX) — May 7, 2020

SCYNEXIS INC (SCYX) (CIK 0001178253)
Date: May 7, 2020 · CIK: 0001178253 · Accession: 0000000000-20-004005

Regulatory Compliance Offering / Registration Process Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237952

Date
May 7, 2020
Author
Scott Sukenick
Form
UPLOAD
Company
SCYNEXIS INC (SCYX) (CIK 0001178253)

Letter

United States securities and exchange commission logo May 7, 2020 Scott Sukenick General Counsel SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 Re:SCYNEXIS, Inc. Registration Statement on Form S-3 Filed May 1, 2020 File No. 333-237952 Dear Mr. Sukenick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at (202) 551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brett White, Esq., Cooley LLP

Show Raw Text
United States securities and exchange commission logo
May 7, 2020
Scott Sukenick
General Counsel
SCYNEXIS, Inc.
1 Evertrust Plaza, 13th Floor
Jersey City, New Jersey 07302-6548
Re:SCYNEXIS, Inc.
Registration Statement on Form S-3
Filed May 1, 2020
File No. 333-237952
Dear Mr. Sukenick:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at (202) 551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Brett White, Esq., Cooley LLP